Reports Q3 revenue EUR 57.84M vs. EUR 48.03M last year. “2024 has been another transformative year for Ascendis. Now, all three of our ...
Ascendis Pharma (ASND) is scheduled to announce Q3 earnings results on Thursday, November 14th, after market close. The ...
GlobalData on MSN9d
Novo Nordisk signs $285m deal with Ascendis to create once-monthly GLP-1RANovo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them ...
Buying $100 In ASND: If an investor had bought $100 of ASND stock 15 years ago, it would be worth $5,581.08 today based on a ...
The Danish pharma group is pledging $285 million in upfront and milestone payments for the lead GLP-1 asset in the ...
Cantor Fitzgerald restated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND – Free Report) in a report published on Monday, Benzinga reports. They currently have a $170.00 ...
The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...
The Danish pharmaceutical giant is putting up $285 million to begin a strategic alliance granting the pharmaceutical giant access to Ascendis Pharma technology that could develop its drugs for ...
On Monday, Ascendis Pharma A/S (NASDAQ:ASND) granted Novo Nordisk A/S (NYSE:NVO) an exclusive worldwide license. The pact ...
The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Ascendis Pharma, and Ultragenyx Pharmaceutical. According to TipRanks, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback